Pfizer Inc. $PFE Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 734,811 shares of the biopharmaceutical company’s stock after selling 20,502 shares during the quarter. Ingalls & Snyder LLC’s holdings in Pfizer were worth $18,723,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Curio Wealth LLC grew its position in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the third quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the second quarter valued at approximately $30,000. True Wealth Design LLC increased its position in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE opened at $27.37 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The firm has a market capitalization of $155.62 billion, a PE ratio of 20.13 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm’s 50-day moving average price is $25.88 and its 200 day moving average price is $25.26.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted $0.63 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s payout ratio is 126.47%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Morgan Stanley decreased their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.